Wendy Guy - 28 Jul 2025 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Reporting relationship: Chief Administrative Officer
Issuer ticker: PCSA
Reported as of: 28 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jul 2025, 16:36:46 UTC
Prior SEC filing: 18 Sep 2025
Next SEC filing: 03 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Wendy Guy by Michael B. Kirwan, as Attorney-in-Fact

Key filing fact

Wendy Guy filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 28 Jul 2025.

Key facts

This page summarizes Wendy Guy's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Jul 2025, 16:36.

Change

Previous filing in this sequence was filed on 18 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001799360 Primary reporting owner

Guy Wendy

Relationship: Chief Administrative Officer
Address: C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH
Signature: /s/ Wendy Guy by Michael B. Kirwan, as Attorney-in-Fact
Signature date: 28 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCSA transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +1,366,046
Change %: +13095%
Price: $0.000000
Shares after: 1,376,478
Date: 24 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,366,046
Exercise price: $0.000000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,349,245 shares are subject to stockholder approval of the revised Omnibus Plan.

Footnote F2

Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.